Physician profile
Valeri Koganski
NPI 1285696948
$17,082.46
in general payments reported to CMS, 2019-2025
69 companies · $2,016 in 2025
The $2,016 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,166 · 2020: $1,984 · 2021: $2,745 · 2022: $2,782 · 2023: $2,714 · 2024: $2,676 · 2025: $2,016.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,405.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,786.97 | 2019-2025 | |
| Novo Nordisk INC | $1,571.12 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $1,459.58 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $1,212.07 | 2019-2025 | Evenity, Prolia, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,139.91 | 2019-2025 | Xifaxan, Cycloset |
| Astrazeneca Pharmaceuticals LP | $922.40 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Radius Health, INC. | $721.91 | 2019-2025 | Tymlos |
| Pfizer INC. | $675.37 | 2019-2025 | |
| Glaxosmithkline, LLC. | $515.52 | 2019-2023 | Shingrix, Trelegy Ellipta, Bexsero |
| Mylan Specialty L.P. | $482.50 | 2019-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $479.94 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $467.27 | 2019-2024 | Jardiance |
| Astellas Pharma US INC | $443.85 | 2019-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $443.03 | 2022-2025 | |
| Vivus LLC | $378.47 | 2019-2025 | Qsymia, Pancreaze |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $359.80 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $353.47 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Corcept Therapeutics | $343.99 | 2023-2025 | Korlym |
| Abbott Laboratories | $329.48 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Exact Sciences Corporation | $233.36 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $197.22 | 2019-2024 | Gattex |
| Esperion Therapeutics, INC. | $181.62 | 2021-2025 | Nexletol |
| Viatris Specialty LLC | $180.10 | 2025 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $177.27 | 2019-2022 | |
| Eisai INC. | $137.59 | 2020-2021 | |
| Heartflow, INC. | $129.33 | 2025 | |
| Shire North American Group INC | $119.53 | 2019 | |
| Alexion Pharmaceuticals, INC. | $115.30 | 2020-2024 | Ultomiris |
| Verona Pharma, INC. | $114.46 | 2025 | Ohtuvayre |
| Avanir Pharmaceuticals, INC. | $112.80 | 2019-2021 | |
| Almatica Pharma LLC | $100.21 | 2024-2025 | Teriparatide |
| Sumitomo Pharma America, INC. | $89.02 | 2024-2025 | Gemtesa |
| Sunovion Pharmaceuticals INC. | $85.61 | 2019-2021 | |
| Boston Scientific Corporation | $73.75 | 2024-2025 | General - Dbs, Bodyguardian |
| Inspire Medical Systems, INC. | $70.41 | 2024 | Inspire |
| Daiichi Sankyo INC. | $66.98 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $65.41 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $54.32 | 2020-2024 | Eliquis, Camzyos |
| Seqirus USA INC | $39.08 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $38.66 | 2019 | |
| Edwards Lifesciences Corporation | $38.22 | 2023-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Xeris Pharmaceuticals, INC. | $32.69 | 2025 | Recorlev |
| Tactile Systems Technology INC | $31.76 | 2024 | Entre Plus, Flexitouch Plus |
| Intra-Sana Laboratories | $30.80 | 2023 | Reltone 200 Mg, Reltone 400 Mg, Glycate |
| Digestive Care, INC. | $30.13 | 2025 | Pertzye |
| Allergan, INC. | $27.12 | 2019 | |
| Pulmonx Corporation | $25.78 | 2025 | Pulmonx Chartis Tablet Console, Chartis Catheter, Zephyr Endobronchial Valve |
| Horizon Therapeutics Plc | $24.61 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $23.41 | 2023 | Kristalose |
| Scilex Pharmaceuticals INC. | $20.46 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $20.41 | 2024 | Evkeeza |
| Ultragenyx Pharmaceutical INC. | $20.19 | 2022 | |
| Aimmune Therapeutics, INC. | $19.85 | 2024 | |
| Dexcom, INC. | $19.62 | 2024 | Dexcom G6 Transmitter |
| Celgene Corporation | $19.52 | 2019 | |
| Idorsia Pharmaceuticals US INC | $19.43 | 2023 | Quviviq |
| Philips North America LLC | $18.95 | 2020 | |
| Sanofi-Aventis U.S. LLC | $18.24 | 2019 | |
| Linus Health, INC. | $17.93 | 2023 | |
| Alvogen INC | $17.81 | 2025 | Teriparatide |
| Currax Pharmaceuticals LLC | $16.57 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.56 | 2025 | Rexulti |
| Tanabe Pharma America, INC. | $16.22 | 2022 | |
| Nabriva Therapeutics, Plc | $16.11 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $16.00 | 2023 | Nuedexta |
| Acella Pharmaceuticals, LLC | $14.60 | 2024 | NP Thyroid 60 |
| Janssen Pharmaceuticals, INC | $14.24 | 2019 | |
| Azurity Pharmaceuticals, INC. | $13.31 | 2023 | Adthyza |
| Sanofi Pasteur INC. | $13.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Valeri Koganski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.